BioSpace News Archive

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the fourth quarter and full year 2021 and provided updates across the company’s pipeline of novel NMDA receptor modulators.

ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, announced that Company management will participate in the Cantor Virtual Rare Orphan Disease Summit on March 29 as part of the RNA Therapeutics in Rare Diseases panel from 2:45-3:45pm EDT.

LogicBio® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Frederic Chereau, will present a company overview at the H.C. Wainwright Gene Therapy and Gene Editing Conference.

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced that the company will release fourth quarter and full year 2021 financial results on Tuesday, March 29, 2022 after the close of market.

Growing applications of cold plasma in the healthcare industry, such as in wound healing and blood coagulation, is a major factor expected to drive market revenue growth.

Growing demand for better cost management and claim management solutions in the healthcare industry is one of the major factors expected to drive the global market revenue growth.

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that John McKew, PhD, President and Chief Scientific Officer of Lumos Pharma, will participate in a panel discussion at the Cantor Rare Disease Symposium at the end of March 2022.

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), announced today that an abstract highlighting the clinical trial protocol utilizing the RECELL® Autologous Cell Harvesting Device (RECELL® System) to treat vitiligo will be presented at the Global Vitiligo Foundation Annual Scientific Symposium.

Ascendis Pharma A/S announced its intention to offer, subject to market and other conditions, US$500,000,000 aggregate principal amount of convertible senior notes due 2028 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

RVL Pharmaceuticals plc today announced that the Company will release its 2021 fourth quarter and full year financial results and provide an update of its first quarter 2022 Medical Aesthetic launch on Wednesday, March 30, 2022, after the close of the U.S. financial markets.